Powles T, Durán I, van der Heijden M, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018; 391: 748–57—In the Results section of this Article, in the sentence that reads “For patients receiving chemotherapy, vinflunine outperformed study expectations; unstratified HRs were 0·95 (95% CI 0·62–1·45) and 0·69 (0·44–1·10) in subgroups based on chemotherapy stratification with vinflunine (n=106) and taxanes (n=128), respectively”, the totals for vinflunine and taxanes are the wrong way around. The sentence should read “For patients receiving chemotherapy, vinflunine outperformed study expectations; unstratified HRs were 0·95 (95% CI 0·62–1·45) and 0·69 (0·44–1·10) in subgroups based on chemotherapy stratification with vinflunine (n=128) and taxanes (n=106), respectively.” These corrections have been made to the online version as of Oct 18, 2018.

中文翻译：

---

错误部

Powles T，DuránI，van der Heijden M等。铂治疗的局部晚期或转移性尿路上皮癌（IMvigor211）患者的阿特珠单抗与化疗的比较：一项多中心，开放标签，3期随机对照试验。柳叶刀2018; 391：748-57—在本文的“结果”部分中，句子为：“对于接受化疗的患者，长春氟宁优于研究预期；根据使用长春氟宁（n = 106）和紫杉烷类药物（n = 128）进行化学分层的亚组，未分层的HRs为0·95（95％CI 0·62-1·45）和0·69（0·44-1·10） ）”，长春氟宁和紫杉烷的总量是错误的计算方法。该句子应显示为“对于接受化疗的患者，长春氟宁优于研究预期；基于用长春氟宁（n = 128）和紫杉烷类药物（n = 106）进行化学分层的亚组，未分层的HRs为0·95（95％CI 0·62-1·45）和0·69（0·44-1·10） ）， 分别。” 截至2018年10月18日，已对在线版本进行了更正。